Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8329644 | 0.87 | NOS1 (0.33) | KMT2AMEN1GAALMNACA1 | |
| SCHEMBL1922911 | 0.84 | CA2 (0.47) | KMT2AMEN1GAACA1CA2 | |
| SCHEMBL26100054 | 0.82 | KMT2A (0.38) | KMT2AMEN1GAALMNADGAT1 | |
| SCHEMBL218283 | 0.79 | CA1 (0.36) | KMT2AMEN1GAALMNADGAT1 | |
| SCHEMBL6337940 | 0.79 | ALDH1A1 (0.42) | KMT2AMEN1GAALMNADGAT1 | |
| SCHEMBL1803154 | 0.78 | CA2 (0.43) | KMT2AMEN1GAALMNADGAT1 | |
| SCHEMBL375812 | 0.77 | NOS1 (0.37) | KMT2AMEN1GAALMNADGAT1 | |
| SCHEMBL4610670 | 0.77 | CYP1A2 (0.49) | TDP1CTSK | |
| Water SCHEMBL27597678 | 0.76 | CA2 (0.42) | KMT2AMEN1GAALMNADGAT1 | |
| SCHEMBL6932447 | 0.76 | KMT2A (0.36) | KMT2AMEN1GAALMNADGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116041180-A | Simple method for preparing 3-bromo-2-bromomethylpropionate tert-butyl ester | 海门瑞一医药科技有限公司 | 2023-05-02 | — | — | CN | claimed |
| EP-4696329-A1 | ANTI-ROR1 ANTIBODY AND DRUG CONJUGATE THEREOF | BioRay Pharmaceutical Co., Ltd. (CN) | 2026-02-18 | — | — | EP | disclosed |
| US-20240425465-A1 | PYRIDAZINEDIONE-BASED HETEROBICYCLIC COVALENT LINKERS AND METHODS AND APPLICATIONS THEREOF | SYNTABIO LLC | 2024-12-26 | — | — | US | disclosed |
| WO-2024213040-A1 | ANTI-ROR1 ANTIBODY AND DRUG CONJUGATE THEREOF | 浙江博锐生物制药有限公司 | 2024-10-17 | — | — | WO | disclosed |
| EP-4422633-A1 | PYRIDAZINEDIONE-BASED HETEROBICYCLIC COVALENT LINKERS AND METHODS AND APPLICATIONS THEREOF | Syntabio LLC (US) | 2024-09-04 | — | — | EP | disclosed |
| WO-2023076848-A1 | PYRIDAZINEDIONE-BASED HETEROBICYCLIC COVALENT LINKERS AND METHODS AND APPLICATIONS THEREOF | SYNTABIO LLC (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023076848-A1 | PYRIDAZINEDIONE-BASED HETEROBICYCLIC COVALENT LINKERS AND METHODS AND APPLICATIONS THEREOF | SYNTABIO LLC (US) | 2023-05-04 | — | — | WO | disclosed |
| CN-116041180-A | Simple method for preparing 3-bromo-2-bromomethylpropionate tert-butyl ester | 海门瑞一医药科技有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-116041180-A | Simple method for preparing 3-bromo-2-bromomethylpropionate tert-butyl ester | 海门瑞一医药科技有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-116041180-A | Simple method for preparing 3-bromo-2-bromomethylpropionate tert-butyl ester | 海门瑞一医药科技有限公司 | 2023-05-02 | — | — | CN | disclosed |
| US-8906930-B2 | Quinazoline derivatives | MERCK PATENT GMBH (DE) | 2014-12-09 | — | — | US | disclosed |
| US-8906930-B2 | Quinazoline derivatives | MERCK PATENT GMBH (DE) | 2014-12-09 | — | — | US | disclosed |
| US-8906930-B2 | Quinazoline derivatives | MERCK PATENT GMBH (DE) | 2014-12-09 | — | — | US | disclosed |
| EP-2504314-A1 | QUINAZOLINE DERIVATIVES | Merck Patent GmbH (DE) | 2012-10-03 | — | — | EP | disclosed |
| US-20120238582-A1 | QUINAZOLINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-09-20 | — | — | US | disclosed |
| US-20120238582-A1 | QUINAZOLINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-09-20 | — | — | US | disclosed |
| WO-2011060873-A1 | QUINAZOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011060873-A1 | QUINAZOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425465-A1 | PYRIDAZINEDIONE-BASED HETEROBICYCLIC COVALENT LINKERS AND METHODS AND APPLICATIONS THEREOF | P4HB, PLPBP, PTMS | KMT2A 3593/4885MEN1 4628/4885GAA 4418/4885 |
| US-20120238582-A1 | QUINAZOLINE DERIVATIVES | HSP90AB1, HSP90AA1, HSP90B1 | KMT2A 4002/4885MEN1 4488/4885GAA 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.